Alto Neuroscience (ANRO) Competitors $6.10 +0.22 (+3.66%) Closing price 10/17/2025 03:58 PM EasternExtended Trading$6.12 +0.03 (+0.49%) As of 10/17/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANRO vs. CMPS, NAGE, SIGA, CMPX, OPT, SVRA, KALV, BCYC, CTMX, and RGNXShould you be buying Alto Neuroscience stock or one of its competitors? The main competitors of Alto Neuroscience include COMPASS Pathways (CMPS), Niagen Bioscience (NAGE), Siga Technologies (SIGA), Compass Therapeutics (CMPX), Opthea (OPT), Savara (SVRA), KalVista Pharmaceuticals (KALV), Bicycle Therapeutics (BCYC), CytomX Therapeutics (CTMX), and REGENXBIO (RGNX). These companies are all part of the "pharmaceutical products" industry. Alto Neuroscience vs. Its Competitors COMPASS Pathways Niagen Bioscience Siga Technologies Compass Therapeutics Opthea Savara KalVista Pharmaceuticals Bicycle Therapeutics CytomX Therapeutics REGENXBIO COMPASS Pathways (NASDAQ:CMPS) and Alto Neuroscience (NYSE:ANRO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership. Is CMPS or ANRO more profitable? Alto Neuroscience's return on equity of -44.34% beat COMPASS Pathways' return on equity.Company Net Margins Return on Equity Return on Assets COMPASS PathwaysN/A -87.89% -57.77% Alto Neuroscience N/A -44.34%-36.73% Do analysts prefer CMPS or ANRO? COMPASS Pathways presently has a consensus target price of $16.00, indicating a potential upside of 145.40%. Alto Neuroscience has a consensus target price of $9.80, indicating a potential upside of 60.79%. Given COMPASS Pathways' stronger consensus rating and higher possible upside, equities analysts clearly believe COMPASS Pathways is more favorable than Alto Neuroscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score COMPASS Pathways 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67Alto Neuroscience 1 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.44 Does the media refer more to CMPS or ANRO? In the previous week, COMPASS Pathways had 9 more articles in the media than Alto Neuroscience. MarketBeat recorded 10 mentions for COMPASS Pathways and 1 mentions for Alto Neuroscience. COMPASS Pathways' average media sentiment score of 0.52 beat Alto Neuroscience's score of 0.00 indicating that COMPASS Pathways is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment COMPASS Pathways 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Alto Neuroscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders believe in CMPS or ANRO? 46.2% of COMPASS Pathways shares are held by institutional investors. 3.9% of COMPASS Pathways shares are held by insiders. Comparatively, 11.1% of Alto Neuroscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more volatility & risk, CMPS or ANRO? COMPASS Pathways has a beta of 2.21, indicating that its stock price is 121% more volatile than the S&P 500. Comparatively, Alto Neuroscience has a beta of 2, indicating that its stock price is 100% more volatile than the S&P 500. Which has higher earnings & valuation, CMPS or ANRO? COMPASS Pathways is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCOMPASS PathwaysN/AN/A-$155.12M-$1.84-3.54Alto NeuroscienceN/AN/A-$61.43M-$2.39-2.55 SummaryCOMPASS Pathways beats Alto Neuroscience on 8 of the 13 factors compared between the two stocks. Get Alto Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for ANRO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANRO vs. The Competition Export to ExcelMetricAlto NeuroscienceMED IndustryMedical SectorNYSE ExchangeMarket Cap$159.21M$3.39B$6.09B$21.77BDividend YieldN/A2.28%5.73%3.62%P/E Ratio-2.5522.4484.5232.40Price / SalesN/A267.64519.3358.86Price / CashN/A46.5937.1624.37Price / Book1.0810.4112.244.59Net Income-$61.43M-$52.47M$3.32B$1.01B7 Day Performance7.65%2.32%1.26%1.32%1 Month Performance49.02%11.14%6.29%-1.45%1 Year Performance-57.76%11.15%59.93%9.57% Alto Neuroscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANROAlto Neuroscience1.9304 of 5 stars$6.10+3.7%$9.80+60.8%-57.3%$159.21MN/A-2.55N/ACMPSCOMPASS Pathways2.9704 of 5 stars$6.29+1.1%$16.00+154.4%+4.0%$596.76MN/A-3.42120News CoverageNAGENiagen Bioscience2.6282 of 5 stars$7.46-0.3%$13.42+79.9%N/A$596.55M$99.60M35.53120SIGASiga Technologies2.1478 of 5 stars$8.26+0.5%N/A+17.4%$588.60M$138.72M7.3140Options VolumeCMPXCompass Therapeutics2.4362 of 5 stars$4.28+0.9%$13.10+206.1%+123.6%$586.32M$850K-9.5120Gap DownOPTOpthea0.3538 of 5 stars$3.41+7.2%$1.33-60.9%-32.2%$583.10M$30K0.008News CoverageAnalyst ForecastGap UpHigh Trading VolumeSVRASavara3.0747 of 5 stars$3.41+1.2%$7.50+119.9%-1.1%$582.46MN/A-6.8220Trending NewsAnalyst UpgradeAnalyst RevisionKALVKalVista Pharmaceuticals3.6488 of 5 stars$11.32-1.6%$26.43+133.5%-8.2%$581.02MN/A-2.87100BCYCBicycle Therapeutics3.541 of 5 stars$8.12-2.4%$22.22+173.7%-69.4%$576.63M$35.28M-2.31240News CoverageAnalyst ForecastCTMXCytomX Therapeutics4.3117 of 5 stars$3.40+1.2%$5.42+59.3%+175.9%$554.11M$138.10M6.07170RGNXREGENXBIO4.423 of 5 stars$11.34+3.8%$28.38+150.2%+10.7%$551.61M$83.33M-3.30370Gap Down Related Companies and Tools Related Companies COMPASS Pathways Competitors Niagen Bioscience Competitors Siga Technologies Competitors Compass Therapeutics Competitors Opthea Competitors Savara Competitors KalVista Pharmaceuticals Competitors Bicycle Therapeutics Competitors CytomX Therapeutics Competitors REGENXBIO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ANRO) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersHoly ****... This could actually MAGAA new document circulating from Washington is stirring major controversy — one that some say could redefine Am...StocksToTrade | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA Worldwide Gold Lockdown Is Now UnderwayCentral banks around the world are hoarding gold at one of the fastest rates in history — and former Goldman S...Stansberry Research | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alto Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alto Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
